The Role of Accurate Antineoplastic Drug Administration in Optimizing Patient-Centered Cancer Care

As rapid advancements are occurring in the ever-expanding oncology field, drug volumes are shrinking and leaving nurses tasked with the challenge to deliver full doses safely and within the appropriate allotted time. New subcutaneous drug formulations are also emerging, offering patients less-invasive therapies but also creating a need for further training in administering these agents. Education on accurate administration of antineoplastic drugs is necessary to make sure patients are not underdosed, reduce patient chair time, decrease staff exposure to hazardous drugs and enhance overall patient outcomes.

Target Audience

This program is designed to meet the educational needs of oncology nurses who treat people with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Understand the critical importance of accurate drug administration in the oncology setting and become familiarized with the most up-to-date best practices. 
  • Identify different routes and techniques of administration of antineoplastic drugs as newer therapies are becoming available. 
  • Recognize the obstacles that oncology nurses face when trying to administer full doses of small drug volumes and learn ways to work with the interprofessional team to improve the drug delivery process that enhances patient and nurse safety, improves patient wait times, and prevents suboptimal dosing.  
Additional information
Supporters: 

This activity is supported by educational grants from:

  • AstraZeneca
  • Ipsen Biopharmaceuticals, Inc.
  • Novartis

This activity is supported through independent educational grants from:

  • Merck & Co., Inc., Rahway, NJ, USA
  • Regeneron Pharmaceuticals, Inc.

Supported by a grant from Pfizer Inc.

This educational activity is supported by an independent medical education grant from GSK.

Course summary
Available credit: 
  • 0.75 ANCC contact hours
    • 0.75 ANCC Pharmacology Contact Hours
  • 0.75 Participation
Course opens: 
06/15/2026
Course expires: 
03/01/2027
Part of: 
Recorded Presentations from the NCCN 2026 Nursing Program: Advancing Oncology Nursing™
MiKaela Olsen, DNP, APRN-CNS, AOCNS, FAAN
Johns Hopkins Kimmel Cancer Center
 
NCCN Continuing Education Disclosure Policy
 
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
 
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 
 
Definitions  
 
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 
 
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
 
Faculty Disclaimers  
 
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery. Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
 
Faculty Disclosures
 
The faculty listed below have no relevant financial relationships with ineligible companies to disclose.

Amanda E. Visnick, RN, BSN, OCN (Nursing Program Moderator) 
 

The faculty listed below has the following relevant financial relationship with an ineligible company to disclose. The relevant financial relationship listed for this individual has been mitigated. 

MiKaela Olsen, DNP, APRN-CNS, AOCNS, FAAN
BD: Consulting Fee; Honoraria

NCCN Staff Disclosures
 
None of the planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
image

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Nurses: NCCN designates this educational activity for a maximum of 0.75 contact hour. This activity offers 0.75 pharmacotherapeutic contact hour for nurses.

Available Credit

  • 0.75 ANCC contact hours
    • 0.75 ANCC Pharmacology Contact Hours
  • 0.75 Participation
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need: 

  • A device with an Internet connection and sound playback capability (speakers or a headset) 
  • Adobe Reader or other PDF reader software for certificate viewing/printing